BioFluidica Announces $6 Million Series B2 Funding to Support the Commercialization of Its Liquid Biopsy Microfluidics Platform, the LiquidScan™, and the Development of Its Advanced Handheld COVID-19 Detection Device for Consumer At-Home Testing

On February 8, 2022, BioFluidica, Inc., a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis, announced that it has raised over $6 million in the initial closings of its Series B2 financing. Additional closings in this targeted $10 million financing are anticipated following successful completion of development milestones relating to BioFluidica's handheld infectious disease detection device using nanofluidics for ultrafast high-sensitivity detection of virus particles. The funding round was led by BioFluidica's existing investor base, with participation from new investors.

Login Or Register To Read Full Story